ReviewCurrent opinion in biotechnology2008
Bacterial therapies: completing the cancer treatment toolbox.
Review in Current opinion in biotechnology, 2008. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 31 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
31 citing papers in PubMed, 87 citations in OpenAlex.
- What Does Bacteria Have to Do with Cancer? The Influence of the Body's Microbiota on Cancer in Cats and Dogs.International journal of molecular sciences · 2026Review
- Systemic administration ofJournal for immunotherapy of cancer · 2025Article
- Optimizing the Efficacy of Vaccine-Induced Immunotherapy in Melanomas.Bulletin of mathematical biology · 2025Article
- Preparation of environmentally responsive PDA&DOX@LAC live drug carrier for synergistic tumor therapy.Scientific reports · 2024Article
- Bacterial carrier-mediated drug delivery systems: a promising strategy in cancer therapy.Frontiers in bioengineering and biotechnology · 2024Review
- Recent advances in bacterial therapeutics based on sense and response.Acta pharmaceutica Sinica. B · 2023Review
- Bacteria and macrophages in the tumor microenvironment.Frontiers in microbiology · 2023Review
- Design of combination therapy for engineered bacterial therapeutics in non-small cell lung cancer.Scientific reports · 2022Article
- Review
- Coating bacteria for anti-tumor therapy.Frontiers in bioengineering and biotechnology · 2022Review
- A novel tumor-targeting strain ofFrontiers in bioengineering and biotechnology · 2022Article
- Bacterial-Based Cancer Therapy (BBCT): Recent Advances, Current Challenges, and Future Prospects for Cancer Immunotherapy.Vaccines · 2021Review
- Microbiome in human cancers.Access microbiology · 2021Review
- Anti-tumor efficacy of plasmid encoding emm55 in a murine melanoma model.Cancer immunology, immunotherapy : CII · 2020Article
- Engineering bacteria for cancer therapy.Emerging topics in life sciences · 2019Article
- Review
- Targeted inactivation ofPeerJ · 2019Article
- A microfluidic device for studying chemotaxis mechanism of bacterial cancer targeting.Scientific reports · 2018Article
- Microfluidic Device to Quantify the Behavior of Therapeutic Bacteria in Three-Dimensional Tumor Tissue.Methods in molecular biology (Clifton, N.J.) · 2016Article
- Potent and tumor specific: arming bacteria with therapeutic proteins.Therapeutic delivery · 2015Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 1 institution in 1 country.
Funding
Abstract
Current cancer therapies have limited efficacy because they are highly toxic, ineffectively target tumors, and poorly penetrate tumor tissue. Engineered bacteria have the unique potential to overcome these limitations by actively targeting all tumor regions and delivering therapeutic payloads. Examples of transport mechanisms include specific chemotaxis, preferred growth, and hypoxic germination. Deleting the ribose/galactose chemoreceptor has been shown to cause bacterial accumulation in therapeutically resistant tumor regions. Recent advances in engineered therapeutic delivery include temporal control of cytotoxin release, enzymatic activation of pro-drugs, and secretion of physiologically active biomolecules. Bacteria have been engineered to express tumor-necrosis-factor-alpha, hypoxia-inducible-factor-1-alpha antibodies, interleukin-2, and cytosine deaminase. Combining these emerging targeting and therapeutic delivery mechanisms will yield a complete treatment toolbox and increase patient survival.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.